201 related articles for article (PubMed ID: 23570263)
1. TP53 p.R337H is a conditional cancer-predisposing mutation: further evidence from a homozygous patient.
Giacomazzi J; Selistre S; Duarte J; Ribeiro JP; Vieira PJ; de Souza Macedo G; Rossi C; Czepielewski M; Netto CB; Hainaut P; Ashton-Prolla P
BMC Cancer; 2013 Apr; 13():187. PubMed ID: 23570263
[TBL] [Abstract][Full Text] [Related]
2. Li-Fraumeni and Li-Fraumeni-like syndrome among children diagnosed with pediatric cancer in Southern Brazil.
Giacomazzi J; Selistre SG; Rossi C; Alemar B; Santos-Silva P; Pereira FS; Netto CB; Cossio SL; Roth DE; Brunetto AL; Zagonel-Oliveira M; Martel-Planche G; Goldim JR; Hainaut P; Camey SA; Ashton-Prolla P
Cancer; 2013 Dec; 119(24):4341-9. PubMed ID: 24122735
[TBL] [Abstract][Full Text] [Related]
3. Clinical spectrum of Li-Fraumeni syndrome/Li-Fraumeni-like syndrome in Brazilian individuals with the TP53 p.R337H mutation.
Ferreira AM; Brondani VB; Helena VP; Charchar HLS; Zerbini MCN; Leite LAS; Hoff AO; Latronico AC; Mendonca BB; Diz MDPE; de Almeida MQ; Fragoso MCBV
J Steroid Biochem Mol Biol; 2019 Jun; 190():250-255. PubMed ID: 30974190
[TBL] [Abstract][Full Text] [Related]
4. p53 signaling pathway polymorphisms, cancer risk and tumor phenotype in TP53 R337H mutation carriers.
Macedo GS; Vieira IA; Vianna FSL; Alemar B; Giacomazzi J; Brandalize APC; Caleffi M; Volc SM; de Campos Reis Galvão H; Palmero EI; Achatz MI; Ashton-Prolla P
Fam Cancer; 2018 Apr; 17(2):269-274. PubMed ID: 28756477
[TBL] [Abstract][Full Text] [Related]
5. The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families.
Achatz MI; Olivier M; Le Calvez F; Martel-Planche G; Lopes A; Rossi BM; Ashton-Prolla P; Giugliani R; Palmero EI; Vargas FR; Da Rocha JC; Vettore AL; Hainaut P
Cancer Lett; 2007 Jan; 245(1-2):96-102. PubMed ID: 16494995
[TBL] [Abstract][Full Text] [Related]
6. Frequency of Thyroid Carcinoma in Brazilian TP53 p.R337H Carriers With Li Fraumeni Syndrome.
Formiga MNDC; de Andrade KC; Kowalski LP; Achatz MI
JAMA Oncol; 2017 Oct; 3(10):1400-1402. PubMed ID: 28114597
[TBL] [Abstract][Full Text] [Related]
7. TP53 germline mutations in adult patients with adrenocortical carcinoma.
Herrmann LJ; Heinze B; Fassnacht M; Willenberg HS; Quinkler M; Reisch N; Zink M; Allolio B; Hahner S
J Clin Endocrinol Metab; 2012 Mar; 97(3):E476-85. PubMed ID: 22170717
[TBL] [Abstract][Full Text] [Related]
8. Penetrance of adrenocortical tumours associated with the germline TP53 R337H mutation.
Figueiredo BC; Sandrini R; Zambetti GP; Pereira RM; Cheng C; Liu W; Lacerda L; Pianovski MA; Michalkiewicz E; Jenkins J; Rodriguez-Galindo C; Mastellaro MJ; Vianna S; Watanabe F; Sandrini F; Arram SB; Boffetta P; Ribeiro RC
J Med Genet; 2006 Jan; 43(1):91-6. PubMed ID: 16033918
[TBL] [Abstract][Full Text] [Related]
9. Clinical and molecular characterization of patients fulfilling Chompret criteria for Li-Fraumeni syndrome in Southern Brazil.
Matzenbacher Bittar C; de Araújo Rocha YM; Vieira IA; Rosset C; Andreis TF; Sartor ITS; Artigalás O; Netto CBO; Alemar B; Macedo GS; Ashton-Prolla P
PLoS One; 2021; 16(9):e0251639. PubMed ID: 34529667
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of the TP53 p.R337H mutation in breast cancer patients in Brazil.
Giacomazzi J; Graudenz MS; Osorio CA; Koehler-Santos P; Palmero EI; Zagonel-Oliveira M; Michelli RA; Scapulatempo Neto C; Fernandes GC; Achatz MI; Martel-Planche G; Soares FA; Caleffi M; Goldim JR; Hainaut P; Camey SA; Ashton-Prolla P
PLoS One; 2014; 9(6):e99893. PubMed ID: 24936644
[TBL] [Abstract][Full Text] [Related]
11. The Brazilian founder mutation TP53 p.R337H is uncommon in Portuguese women diagnosed with breast cancer.
Giacomazzi J; Correia RL; Palmero EI; Gaspar JF; Almeida M; Portela C; Camey SA; Monteiro A; Pinheiro M; Peixoto A; Teixeira MR; Reis RM; Ashton-Prolla P
Breast J; 2014; 20(5):534-6. PubMed ID: 25052705
[TBL] [Abstract][Full Text] [Related]
12. TP53 and CDKN1A mutation analysis in families with Li-Fraumeni and Li-Fraumeni like syndromes.
Andrade RC; Dos Santos AC; de Aguirre Neto JC; Nevado J; Lapunzina P; Vargas FR
Fam Cancer; 2017 Apr; 16(2):243-248. PubMed ID: 27714481
[TBL] [Abstract][Full Text] [Related]
13. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study.
Villani A; Shore A; Wasserman JD; Stephens D; Kim RH; Druker H; Gallinger B; Naumer A; Kohlmann W; Novokmet A; Tabori U; Tijerin M; Greer ML; Finlay JL; Schiffman JD; Malkin D
Lancet Oncol; 2016 Sep; 17(9):1295-305. PubMed ID: 27501770
[TBL] [Abstract][Full Text] [Related]
14. Frequency of the TP53 p.R337H mutation in a Brazilian cohort of pediatric patients with solid tumors.
Feitosa JADS; das Chagas PF; de Sousa GR; Queiroz RGP; Cruzeiro GAV; Tone LG; Borges KS; Valera ET
Mol Biol Rep; 2020 Aug; 47(8):6439-6443. PubMed ID: 32671623
[TBL] [Abstract][Full Text] [Related]
15. MIR605 rs2043556 is associated with the occurrence of multiple primary tumors in TP53 p.(Arg337His) mutation carriers.
Bandeira IC; Vieira IA; Andreis TF; Brussa Reis L; Macedo GS; Vianna FSL; Santos-Silva P; Palmero EI; Galvão HCR; Ramos CRN; Santiago KM; Achatz MI; da Costa AABA; Ashton-Prolla P
Cancer Genet; 2020 Jan; 240():54-58. PubMed ID: 31778928
[TBL] [Abstract][Full Text] [Related]
16. Identification of the
Sandoval RL; Masotti C; de Macedo MP; Ribeiro MFSA; Leite ACR; Meireles SI; Bovolin RM; Santini FC; Munhoz RR; Jardim DLF; Katz A; Camargo AA; Fernandes GDS; Achatz MI
JCO Glob Oncol; 2021 Jul; 7():1141-1150. PubMed ID: 34270331
[TBL] [Abstract][Full Text] [Related]
17. Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort.
Mai PL; Best AF; Peters JA; DeCastro RM; Khincha PP; Loud JT; Bremer RC; Rosenberg PS; Savage SA
Cancer; 2016 Dec; 122(23):3673-3681. PubMed ID: 27496084
[TBL] [Abstract][Full Text] [Related]
18. The Common Germline
Jeffers JR; Pinto EM; Rehg JE; Clay MR; Wang J; Neale G; Heath RJ; Lozano G; Lalli E; Figueiredo BC; Pappo AS; Rodriguez-Galindo C; Chen W; Pounds S; Ribeiro RC; Zambetti GP
Cancer Res; 2021 May; 81(9):2442-2456. PubMed ID: 33637564
[TBL] [Abstract][Full Text] [Related]
19. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes.
Ruijs MW; Verhoef S; Rookus MA; Pruntel R; van der Hout AH; Hogervorst FB; Kluijt I; Sijmons RH; Aalfs CM; Wagner A; Ausems MG; Hoogerbrugge N; van Asperen CJ; Gomez Garcia EB; Meijers-Heijboer H; Ten Kate LP; Menko FH; van 't Veer LJ
J Med Genet; 2010 Jun; 47(6):421-8. PubMed ID: 20522432
[TBL] [Abstract][Full Text] [Related]
20. Contribution of the TP53 R337H mutation to the cancer burden in southern Brazil: Insights from the study of 55 families of children with adrenocortical tumors.
Mastellaro MJ; Seidinger AL; Kang G; Abrahão R; Miranda ECM; Pounds SB; Cardinalli IA; Aguiar SS; Figueiredo BC; Rodriguez-Galindo C; Brandalise SR; Yunes JA; Barros-Filho AA; Ribeiro RC
Cancer; 2017 Aug; 123(16):3150-3158. PubMed ID: 28387921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]